Popular Trials
Placebo +5 More for Type 2 Diabetes
Recruiting0 awardsPhase 2
Brooklyn Center, Minnesota
B2611003 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 6 treatments for 3 months. One of the treatments will be sitagliptin which is an approved drug, and another treatment will be placebo, which does not contain active ingredient.
Placebo +1 More for There is no disease term in this phrase. It describes a study or research.
Recruiting0 awardsPhase 2
Edina, Minnesota
This trial is testing ANG-3070, a new drug, in people with a kidney disease that causes protein loss in urine. The goal is to see if it can improve kidney function and reduce the amount of protein lost.
Organ Preservation Device
OCS Heart System for Heart Transplant
Recruiting1 award10 criteria
Minneapolis, Minnesota
To evaluate the effectiveness of the OCS Heart System to resuscitate, preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation.
Monoclonal Antibodies
Atezolizumab + Standard Therapy for HER2-Positive Breast Cancer
Recruiting1 awardPhase 3
Jonesboro, Arkansas
This trial is studying how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body (metastatic).
Popular Filters
Phase 3 Trials
Monoclonal Antibodies
Rilotumumab +1 More for Lung Cancer
Recruiting2 awardsPhase 2 & 3
Jonesboro, Arkansas
This randomized phase II/III compares rilotumumab when given together with erlotinib hydrochloride against erlotinib hydrochloride alone in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for the met proto-oncogene (MET)/hepatocyte growth factor (HGF) biomarker. HGF can interact with MET and can cause tumor cells to grow more quickly. Rilotumumab may decrease the activity of HGF and may be able to shrink tumors. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving rilotumumab with erlotinib hydrochloride works better than erlotinib hydrochloride alone (standard treatment) in treating squamous cell lung cancer.
Placebo for Oral Mucosal Desquamation
Recruiting2 awardsPhase 3
Minneapolis, Minnesota
RATIONALE: Doxepin hydrochloride may be an effective treatment for oral mucositis pain in patients undergoing radiation therapy with or without chemotherapy. PURPOSE: This randomized phase III trial is studying doxepin hydrochloride to see how well it works compared to placebo in treating oral mucositis pain in patients with head and neck cancer undergoing radiation therapy with or without chemotherapy.
Trials With No Placebo
Anti-metabolites
Decitabine/Cedazuridine +1 More for Myelodysplastic Syndrome
Recruiting1 awardPhase 2
Minneapolis, Minnesota
This trial is testing a new combination of drugs to treat cancer. It uses decitabine/cedazuridine to stop cancer cells from growing and magrolimab to help the immune system destroy them. The goal is to see if this combination is safe and effective for patients who may not respond to usual treatments.
Endocrine Drug Therapy
Symptom Monitoring for Young Women on Hormone Therapy for Breast Cancer
Recruiting1 award13 criteria
Ames, Iowa
This trial will determine if asking about symptoms more often helps young women stay on hormone therapy for breast cancer, reducing side effects and increasing their chances of a successful treatment.
Behavioural Intervention
Cognitive surveys for Brain Tumor
Recruiting1 award7 criteria
Rochester, Minnesota
This study is to evaluate which cognitive-linguistic symptoms are most commonly experienced following brain tumor treatment. Cognitive surveys will be administered after treatment of primary brain tumor cancer.
Monoclonal Antibodies
Rilotumumab +1 More for Lung Cancer
Recruiting2 awardsPhase 2 & 3
Jonesboro, Arkansas
This randomized phase II/III compares rilotumumab when given together with erlotinib hydrochloride against erlotinib hydrochloride alone in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for the met proto-oncogene (MET)/hepatocyte growth factor (HGF) biomarker. HGF can interact with MET and can cause tumor cells to grow more quickly. Rilotumumab may decrease the activity of HGF and may be able to shrink tumors. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving rilotumumab with erlotinib hydrochloride works better than erlotinib hydrochloride alone (standard treatment) in treating squamous cell lung cancer.
Heat Shock Protein Inhibitor
17-AAG for Prostate Cancer
Recruiting1 awardPhase 2
Rochester, Minnesota
This phase II trial is studying how well 17-AAG works in treating patients with metastatic prostate cancer that did not respond to previous hormone therapy. Drugs used in chemotherapy, such as 17-AAG, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.